TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38035766

Group type: EXPERIMENTAL
Intervention: Oral glucose (50-g OGTT)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Isoglycemic IV glucose infusion (IIGI)
Number of subjects: 19
Study: 38035997

Group type: EXPERIMENTAL
Intervention: Diet with C15:0 supplementation
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Diet without C15:0 supplementation
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control (habitual diet and no C15:0 supplementation)
Number of subjects: 88
Study: 38036071

Group type: EXPERIMENTAL
Intervention: Mediterranean Diet
Number of subjects: 805

Group type: COMPARATOR
Intervention: Low-fat Diet
Number of subjects: 805

Group type: EXPERIMENTAL
Intervention: Dietary Antioxidant Index (DAI) components
Number of subjects: 805
Study: 38036166

Group type: EXPERIMENTAL
Intervention: Cervical pessary
Number of subjects: 137

Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 137
Study: 38036220

Group type: EXPERIMENTAL
Intervention: Empagliflozin (SGLTi)
Number of subjects: 40
Study: 38036399

Group type: EXPERIMENTAL
Intervention: Active pelvic movements on a Swiss ball
Number of subjects: 200
Study: 38036487

Group type: EXPERIMENTAL
Intervention: Maribavir 400 mg twice daily
Number of subjects: 547

Group type: COMPARATOR
Intervention: Valganciclovir (dose-adjusted for renal clearance)
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Maribavir
Number of subjects: 547

Group type: COMPARATOR
Intervention: Valganciclovir
Number of subjects: 547
Study: 38036712

Group type: EXPERIMENTAL
Intervention: Entinostat 8 mg PO days 1 and 15 + Pembrolizumab 200 mg IV day 1 every 21 days
Number of subjects: 28
Study: 38036720

Group type: EXPERIMENTAL
Intervention: Eftozanermin alfa monotherapy 2.5-15 mg/kg on Day 1 or Days 1/8 of a 21-day cycle
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Eftozanermin alfa monotherapy or combination therapy with oral venetoclax 400-800 mg daily (1.25-7.5 mg/kg Days 1/8/15 of a 21-day cycle)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Eftozanermin alfa (3.75 or 7.5 mg/kg Days 1/8/15/22 of a 28-day cycle) and FOLFIRI regimen with/without bevacizumab
Number of subjects: 153
Study: 38036761

Group type: EXPERIMENTAL
Intervention: Bifidobacterium breve Bif195 (≥10 billion CFU) co-administered with aspirin 300 mg daily for 4 weeks
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 38036930

Group type: EXPERIMENTAL
Intervention: Von Willebrand factor (VWF) concentrates-pure or in association with Factor VIII (FVIII)
Number of subjects: 988

Group type: COMPARATOR
Intervention: Highly purified VWF or VWF combined with FVIII
Number of subjects: 988

Group type: EXPERIMENTAL
Intervention: VWF concentrates
Number of subjects: 988
Study: 38036946

Group type: EXPERIMENTAL
Intervention: Ustekinumab (6 mg/kg IV at Week 0, 90 mg SC at Week 8)
Number of subjects: 323
Study: 38037105

Group type: EXPERIMENTAL
Intervention: Enhanced standard of care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychosocial support
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: mHealth using cellular-enabled electronic dose monitoring
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined mHealth and psychosocial support
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 38037108

Group type: EXPERIMENTAL
Intervention: 1000 mg of CBD
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 38037119

Group type: EXPERIMENTAL
Intervention: Bedaquiline, linezolid, clofazimine, and delamanid (experimental arm)
Number of subjects: 324

Group type: COMPARATOR
Intervention: WHO standard of care for pre-XDR TB (control arm)
Number of subjects: 324
Study: 38037188

Group type: EXPERIMENTAL
Intervention: hp-HMG (225 IU/day)
Number of subjects: 112

Group type: COMPARATOR
Intervention: r-FSH (225 IU/day)
Number of subjects: 112
Study: 38037749

Group type: EXPERIMENTAL
Intervention: Occupational therapy lifestyle intervention
Number of subjects: 40
Study: 38037804

Group type: EXPERIMENTAL
Intervention: Peripheral nerve blocks (PNB)
Number of subjects: 165

Group type: COMPARATOR
Intervention: General anesthesia (GA)
Number of subjects: 165
Study: 38037817

Group type: EXPERIMENTAL
Intervention: Exercise and dietary interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 38037839

Group type: EXPERIMENTAL
Intervention: HS-10352 at 6 mg QD
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: HS-10352 at 8 mg QD
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: HS-10352 (all doses)
Number of subjects: 18
Study: 38038169

Group type: EXPERIMENTAL
Intervention: Lower levels of inactivity
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Physically active older adults
Number of subjects: 184

Group type: COMPARATOR
Intervention: Higher levels of inactivity
Number of subjects: 184

Group type: COMPARATOR
Intervention: Physically inactive participants
Number of subjects: 184
Study: 38038339

Group type: EXPERIMENTAL
Intervention: Low-density-lipoprotein cholesterol (LDL-c) levels modeled as a continuous variable
Number of subjects: 12334

Group type: EXPERIMENTAL
Intervention: LDL-c levels
Number of subjects: 12334
Study: 38038395

Group type: EXPERIMENTAL
Intervention: Prone positioning (at least 4 sessions of 16 hours)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Supine positioning
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Prone positioning
Number of subjects: 170
Study: 38038620

Group type: EXPERIMENTAL
Intervention: Protocolized sedation
Number of subjects: 232

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 232
Study: 38038626

Group type: EXPERIMENTAL
Intervention: Cervarix vaccine
Number of subjects: 3013
Study: 38038829

Group type: EXPERIMENTAL
Intervention: Deep learning autosegmentation models for tumor segmentation
Number of subjects: 259
Study: 38038866

Group type: EXPERIMENTAL
Intervention: Ad5-nCoV vaccine booster dose
Number of subjects: 89
Study: 38039007

Group type: EXPERIMENTAL
Intervention: Voice-based conversational AI application
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 32
Study: 38039341

Group type: EXPERIMENTAL
Intervention: 18-month meditation training
Number of subjects: 137

Group type: COMPARATOR
Intervention: English language training
Number of subjects: 137

Group type: COMPARATOR
Intervention: No-intervention
Number of subjects: 137
Study: 38039357

Group type: EXPERIMENTAL
Intervention: EpCAM-CAR-T cells
Number of subjects: 12
Study: 38039427

Group type: EXPERIMENTAL
Intervention: Canakinumab (200 mg subcutaneously once every 3 weeks)
Number of subjects: 643

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 643

Group type: EXPERIMENTAL
Intervention: Canakinumab plus pembrolizumab and chemotherapy
Number of subjects: 643

Group type: COMPARATOR
Intervention: Placebo plus pembrolizumab and chemotherapy
Number of subjects: 643
Study: 38039429

Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 29
Study: 38039432

Group type: EXPERIMENTAL
Intervention: HRD-S in non-TNBC
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: HRD-S in TNBC
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: HRD-W in non-TNBC
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: HRD-W in TNBC
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: RAD51 low scores in HRD-S non-TNBC
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: RAD51 low scores in HRD-S TNBC
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: RAD51 low scores in HRD-W non-TNBC
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: RAD51 low scores in HRD-W TNBC
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Basal-like PAM50 signature in HRD-S non-TNBC
Number of subjects: 201
Study: 38039511

Group type: EXPERIMENTAL
Intervention: Immune-mediated TTP (iTTP)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Acquired TTP of unidentified mechanism (uTTP)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Congenital TTP (cTTP)
Number of subjects: 108
Study: 38039831

Group type: EXPERIMENTAL
Intervention: Pemigatinib
Number of subjects: 0
Study: 38039991

Group type: EXPERIMENTAL
Intervention: Durvalumab (1500 mg intravenously once every 4 weeks) with chemoradiotherapy
Number of subjects: 770

Group type: COMPARATOR
Intervention: Placebo with chemoradiotherapy
Number of subjects: 770

Group type: EXPERIMENTAL
Intervention: Durvalumab
Number of subjects: 770

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 770
Study: 38039992

Group type: EXPERIMENTAL
Intervention: avasopasem (90 mg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: avasopasem
Number of subjects: 42
Study: 38039993

Group type: EXPERIMENTAL
Intervention: Lenvatinib plus pembrolizumab
Number of subjects: 794

Group type: COMPARATOR
Intervention: Lenvatinib plus placebo
Number of subjects: 794
Study: 38040019

Group type: EXPERIMENTAL
Intervention: Expectancy of gluten intake
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Actual gluten intake
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 84
Study: 38040274

Group type: EXPERIMENTAL
Intervention: Ozanimod
Number of subjects: 1619
Study: 38040277

Group type: EXPERIMENTAL
Intervention: Total parathyroidectomy
Number of subjects: 65

Group type: COMPARATOR
Intervention: Oral cinacalcet
Number of subjects: 65
Study: 38040423

Group type: EXPERIMENTAL
Intervention: Living donor kidney transplantation information delivery
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Transplantation counselling approach
Number of subjects: 20
Study: 38040452

Group type: EXPERIMENTAL
Intervention: Prehospital risk stratification and direct transfer to a PCI centre based on the preHEART score
Number of subjects: 1069
Study: 38040478

Group type: EXPERIMENTAL
Intervention: Daily or event-based oral PrEP (tenofovir disoproxil maleate with emtricitabine)
Number of subjects: 21356

Group type: COMPARATOR
Intervention: Non-trial attendees (control group)
Number of subjects: 21356

Group type: EXPERIMENTAL
Intervention: Trial participants (MSM)
Number of subjects: 21356
Study: 38040541

Group type: EXPERIMENTAL
Intervention: Daily cup of study beans added to usual diet
Number of subjects: 55

Group type: COMPARATOR
Intervention: Usual diet without beans (control)
Number of subjects: 55
Study: 38040875

Group type: EXPERIMENTAL
Intervention: Antenatal corticosteroid therapy (ACS)
Number of subjects: 408
Study: 38040987

Group type: EXPERIMENTAL
Intervention: Cholestasis patients
Number of subjects: 17

Group type: COMPARATOR
Intervention: Controls without cholestasis
Number of subjects: 17
Study: 38041042

Group type: EXPERIMENTAL
Intervention: PT + PEERC
Number of subjects: 54

Group type: COMPARATOR
Intervention: PT
Number of subjects: 54
Study: 38041058

Group type: EXPERIMENTAL
Intervention: HIV testing and ART initiation/adherence among men and women with AHD
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: HIV care decision-making
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Gender-tailored counseling services and community messaging
Number of subjects: 64
Study: 38041070

Group type: EXPERIMENTAL
Intervention: Meal kits (n=35)
Number of subjects: 70

Group type: COMPARATOR
Intervention: No-prep meals (n=35)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 70
Study: 38041077

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: No adjuvant chemotherapy
Number of subjects: 75

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 75
Study: 38041148

Group type: EXPERIMENTAL
Intervention: online cognitive behavioural therapy intervention based on the unified protocol
Number of subjects: 214

Group type: COMPARATOR
Intervention: online progressive muscle relaxation training
Number of subjects: 214

Group type: COMPARATOR
Intervention: waiting-list control group
Number of subjects: 214
Study: 38041177

Group type: EXPERIMENTAL
Intervention: Hyponatremia (natremia <135 mmol/L)
Number of subjects: 1163

Group type: COMPARATOR
Intervention: Normal natremia (135-145 mmol/L)
Number of subjects: 1163

Group type: EXPERIMENTAL
Intervention: Hypernatremia (natremia >145 mmol/L)
Number of subjects: 1163
Study: 38041180

Group type: EXPERIMENTAL
Intervention: m-health self-managed exercise program plus health education
Number of subjects: 0

Group type: COMPARATOR
Intervention: Health education alone
Number of subjects: 0
Study: 38041762

Group type: EXPERIMENTAL
Intervention: Post-COVID syndrome (PCS) patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fully SARS-CoV-2-infection-recovered (CR) participants
Number of subjects: 0

Group type: COMPARATOR
Intervention: SARS-CoV-2-infection-naïve (CN) participants
Number of subjects: 0
Study: 38041959

Group type: EXPERIMENTAL
Intervention: STIM (spatial-temporal integration model)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: STIM
Number of subjects: 169
Study: 38042152

Group type: EXPERIMENTAL
Intervention: Three short-term infections with 50 infectious Necator americanus third-stage filariform larvae (50L3)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 38042167

Group type: EXPERIMENTAL
Intervention: Low-dose CT (LDCT) screening
Number of subjects: 12011
Study: 38042207

Group type: EXPERIMENTAL
Intervention: Endoscopic powered resection (EPR) device
Number of subjects: 65
Study: 38042412

Group type: EXPERIMENTAL
Intervention: 7.5 g GOS/FOS + iron
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: 3 g GOS/FOS + iron
Number of subjects: 191

Group type: COMPARATOR
Intervention: No prebiotics (iron group)
Number of subjects: 191
Study: 38042459

Group type: EXPERIMENTAL
Intervention: hs-cTnI-PATHFAST 0/1h-algorithm
Number of subjects: 1532

Group type: EXPERIMENTAL
Intervention: hs-cTnI-PATHFAST 0/2h-algorithm
Number of subjects: 1532
Study: 38042525

Group type: EXPERIMENTAL
Intervention: Osimertinib plus platinum-pemetrexed (combination)
Number of subjects: 557

Group type: COMPARATOR
Intervention: Osimertinib monotherapy
Number of subjects: 557
Study: 38042773

Group type: EXPERIMENTAL
Intervention: Robot for medication management
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (no robot)
Number of subjects: 110
Study: 38042801

Group type: EXPERIMENTAL
Intervention: BUP-XR 300-mg maintenance dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BUP-XR 100-mg maintenance dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BUP-XR 100-mg and 300-mg maintenance doses
Number of subjects: 0
Study: 38042811

Group type: EXPERIMENTAL
Intervention: Self-measurements of SpO2
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Daily respiratory exercises
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Hospital admission
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Follow-up termination
Number of subjects: 40
Study: 38042851

Group type: EXPERIMENTAL
Intervention: Olipudase alfa treatment for 2 years
Number of subjects: 36

Group type: COMPARATOR
Intervention: Cross-over group after 1 year of olipudase alfa treatment
Number of subjects: 36
Study: 38043045

Group type: EXPERIMENTAL
Intervention: EHR-embedded alert
Number of subjects: 2211

Group type: EXPERIMENTAL
Intervention: Message
Number of subjects: 2211

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2211

Group type: EXPERIMENTAL
Intervention: Alert
Number of subjects: 2211
Study: 38043556

Group type: EXPERIMENTAL
Intervention: ansuvimab
Number of subjects: 787

Group type: EXPERIMENTAL
Intervention: REGN-EB3
Number of subjects: 787

Group type: EXPERIMENTAL
Intervention: remdesivir
Number of subjects: 787

Group type: EXPERIMENTAL
Intervention: ZMapp
Number of subjects: 787
Study: 38043558

Group type: EXPERIMENTAL
Intervention: Lutetium-177
Number of subjects: 200

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 200
Study: 38043867

Group type: EXPERIMENTAL
Intervention: Daytime home parenteral nutrition (HPN)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Overnight home parenteral nutrition (HPN)
Number of subjects: 20
Study: 38043911

Group type: EXPERIMENTAL
Intervention: Minocycline (100 mg, twice daily)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Minocycline
Number of subjects: 159
Study: 38044204

Group type: EXPERIMENTAL
Intervention: givosiran 2.5 mg/kg
Number of subjects: 7

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 7
Study: 38044272

Group type: EXPERIMENTAL
Intervention: Pilocarpine hydrochloride 1.25% (pilo)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 38044419

Group type: EXPERIMENTAL
Intervention: 50 mg eliapixant
Number of subjects: 6
Study: 38044439

Group type: EXPERIMENTAL
Intervention: CMR-ECGI using the reusable, washable vest
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: CMR-ECGI
Number of subjects: 77
Study: 38044460

Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) Tranexamic acid (TXA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) Tranexamic acid (TXA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38045112

Group type: EXPERIMENTAL
Intervention: Hypertension focused ECHO program for Community Health Extension Workers (CHEWs)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Strategies for implementing the ECHO program
Number of subjects: 42
Study: 38045238

Group type: EXPERIMENTAL
Intervention: Oncuria BC multiplex immunoassay
Number of subjects: 36
Study: 38045245

Group type: EXPERIMENTAL
Intervention: Electromagnetic navigational bronchoscopy with integrated digital tomosynthesis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Computed tomography-guided transthoracic needle biopsy (CT-TTNB)
Number of subjects: 0
Study: 38045318

Group type: EXPERIMENTAL
Intervention: WFPB dietary intervention
Number of subjects: 31

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 31
Study: 38045387

Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 vaccine
Number of subjects: 1500
Study: 38045434

Group type: EXPERIMENTAL
Intervention: Gradient Boosting Classifier (GBC) model
Number of subjects: 35389
Study: 38045440

Group type: EXPERIMENTAL
Intervention: Nine serially measured proteins
Number of subjects: 382
Study: 38045443

Group type: EXPERIMENTAL
Intervention: Visitation policies and ward structure changes during COVID-19
Number of subjects: 616

Group type: EXPERIMENTAL
Intervention: Patient characteristics (age, sex, race/ethnicity, admission type, discharge destination)
Number of subjects: 616

Group type: EXPERIMENTAL
Intervention: Participant interviews
Number of subjects: 616
Study: 38045523

Group type: EXPERIMENTAL
Intervention: Angiotensin II infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 38045525

Group type: EXPERIMENTAL
Intervention: Selective Decontamination of the Digestive Tract
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study: 38045529

Group type: EXPERIMENTAL
Intervention: Implementation strategy package (video education, HIV self-testing, and co-location)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison facilities (no strategies implemented)
Number of subjects: 0
Study: 38045767

Group type: EXPERIMENTAL
Intervention: Arthroscopic complete posterior knee capsulotomy
Number of subjects: 15
Study: 38045774

Group type: EXPERIMENTAL
Intervention: Low-power thulium laser enucleation of prostates (ThuLEP)
Number of subjects: 80
Study: 38045803

Group type: EXPERIMENTAL
Intervention: Monthly BUP-XR (Sublocade;® two injections of 300 mg, then four maintenance injections of 100 mg or 300 mg) for 24 weeks
Number of subjects: 314

Group type: COMPARATOR
Intervention: Daily standard-of-care (SoC) medication (liquid methadone 60-120 mg or sublingual/transmucosal buprenorphine 8-24 mg) for 24 weeks
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness of BUP-XR versus SoC
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: BUP-XR among participants rated more severe at study baseline
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: BUP-XR among participants in maintenance treatment for more than 28 days
Number of subjects: 314
Study: 38046041

Group type: EXPERIMENTAL
Intervention: Direct-acting antivirals (DAAs) treatment for HCV-viremic patients, with 152 patients linked to care and treated.
Number of subjects: 2336

Group type: EXPERIMENTAL
Intervention: Link-to-care project for HCV treatment.
Number of subjects: 2336
Study: 38046050

Group type: EXPERIMENTAL
Intervention: Internet-based conversational engagement clinical trial (I-CONECT)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Best practice recruitment strategies
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Recruitment criteria adjustments
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Challenges in recruitment
Number of subjects: 39

Group type: COMPARATOR
Intervention: Comparison with White participants
Number of subjects: 39
Study: 38046082

Group type: EXPERIMENTAL
Intervention: Early goal-directed therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study: 38046085

Group type: EXPERIMENTAL
Intervention: Early activity and mobilization
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study: 38046113

Group type: EXPERIMENTAL
Intervention: Goal Management Training (GMT)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 81
Study: 38046145

Group type: EXPERIMENTAL
Intervention: Barrier dressing (adhesive material applied to the skin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No barrier dressing (control group)
Number of subjects: 0
Study: 38046376

Group type: EXPERIMENTAL
Intervention: Nivolumab and Ramucirumab
Number of subjects: 34
Study: 38046390

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 38046409

Group type: EXPERIMENTAL
Intervention: AIaMD assessment of dermoscopic images
Number of subjects: 268
Study: 38046686

Group type: EXPERIMENTAL
Intervention: Targeted Therapeutic Mild Hypercapnia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study: 38046839

Group type: EXPERIMENTAL
Intervention: High flow nasal catheter therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-invasive positive pressure ventilation
Number of subjects: 0
Study: 38046911

Group type: EXPERIMENTAL
Intervention: Finerenone
Number of subjects: 13026

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13026
Study: 38046912

Group type: EXPERIMENTAL
Intervention: F&V + Cook (cooking instructions)
Number of subjects: 142

Group type: COMPARATOR
Intervention: F&V Only (no cooking instructions)
Number of subjects: 142